Complete Filing Data
China SXT Pharmaceuticals, Inc. reported Stockholders Equity of $15.44 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean China SXT Pharmaceuticals, Inc. did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Net Income * | -$3.3M | -$3.1M | -$5.9M | -$5.7M | -$2.7M | -$10.3M | $1.5M | $1.2M | $1.2M |
| Revenue * | $1.7M | $1.9M | $2.0M | $2.6M | $4.8M | $5.2M | $7.0M | $7.0M | $4.9M |
| Comprehensive Income Net Of Tax | -$3.4M | -$3.9M | -$7.1M | -$5.3M | -$1.6M | -$10.9M | $1.3M | $1.4M | $1.1M |
| Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | -$49.7K | -$828.2K | -$1.2M | $428.4K | $1.1M | -$641.1K | -$207.0K | $245.5K | -$75.3K |
| Operating Income Loss | -$2.7M | -$2.5M | -$5.6M | -$5.2M | -$2.2M | -$1.3M | $1.8M | $1.6M | $1.6M |
| Operating Expenses | $3.0M | $3.1M | $6.0M | $6.4M | $5.0M | $4.0M | $2.8M | $1.8M | $709.8K |
| Nonoperating Income Expense | -$623.2K | -$583.3K | -$327.3K | -$218.3K | -$743.8K | -$9.0M | $22.0K | -$4.6K | -$22.0K |
| Gross Profit | $367.4K | $554.0K | $426.3K | $1.3M | $2.8M | $2.7M | $4.6M | $3.4M | $2.3M |
| General And Administrative Expense | $2.8M | $2.6M | $5.6M | $5.5M | $3.4M | $2.5M | $1.2M | $1.3M | $565.5K |
| Cost Of Revenue | $1.4M | $1.4M | $1.5M | $1.4M | $1.9M | $2.5M | $2.4M | $3.6M | $2.6M |
| Accrued Income Taxes Current | $1.0M | $1.1M | $1.1M | $1.2M | $1.2M | $986.8K | $1.1M | $870.5K | |
| Revenues Generated From Third Parties | $1.9M | $2.3M | $3.9M | $4.8M | $6.8M | $5.7M | $4.2M | ||
| Other Nonoperating Income Expense | $149.5K | -$181.6K | $871.7K | -$73.8K | $27.1K | -$3.8K | $18.4K | ||
| Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax | -$49.7K | -$828.2K | -$1.2M | $428.4K | $1.1M | -$641.1K | -$207.0K | ||
| Income Taxes Paid Net | $13.0K | $16.7K | $5.6K | $287.8K | $1.5K | $22.4K | $7.1K | ||
| Income Tax Expense Benefit | $328.1K | -$192.7K | -$101.7K | $252.2K | $440.1K | $395.0K | |||
| Revenue From Related Parties | $339.1K | $885.0K | $330.4K | $212.2K | $1.3M | $731.5K | |||
| Interest Expense | $476.8K | $36.7K | $1.6M | $3.3M | $5.2K | $779.00 | $40.4K | ||
| Selling And Marketing Expense | $289.9K | $433.6K | $387.5K | $924.5K | $1.6M | ||||
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$3.3M | -$3.1M | -$5.9M | -$5.4M | -$2.9M | -$10.4M | $1.8M | ||
| Deferred Income Tax Expense Benefit | $328.1K | -$192.7K | -$101.7K | -$7.7K | -$5.9K | ||||
| Deferred Income Tax Assets Net | $321.4K | $112.8K | $13.5K | $6.2K |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Stockholders Equity | $15.4M | $13.9M | $14.7M | $16.1M | $16.0M | $9.4M | $11.1M | $3.3M | $1.9M | $742.8K |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $18.1M | $12.1M | $17.4M | $15.6M | $13.4M | $7.3M | $9.3M | |||
| Cash And Cash Equivalents At Carrying Value | $18.1M | $12.1M | $17.4M | $13.4M | $7.3M | $9.3M | $657.8K | $65.6K | $11.4K | |
| Retained Earnings Accumulated Deficit | -$28.0M | -$24.7M | -$21.6M | -$15.7M | -$10.0M | -$7.2M | $3.1M | $1.5M | ||
| Property Plant And Equipment Net | $178.6K | $328.8K | $962.2K | $1.2M | $1.4M | $1.6M | $1.2M | $862.5K | ||
| Prepaid Expense And Other Assets Current | $319.1K | $31.6K | $230.6K | $864.7K | $1.9M | $4.6M | $707.3K | $910.6K | ||
| Liabilities Current | $6.0M | $8.9M | $14.5M | $17.1M | $18.6M | $12.3M | $6.3M | $4.4M | ||
| Liabilities And Stockholders Equity | $21.7M | $23.1M | $29.6M | $33.5M | $34.5M | $21.7M | $17.5M | $7.7M | ||
| Liabilities | $6.2M | $9.2M | $14.9M | $17.1M | $18.6M | $12.3M | $6.4M | $4.4M | ||
| Inventory Net | $828.1K | $794.9K | $531.3K | $1.0M | $859.7K | $892.8K | $1.0M | $1.3M | ||
| Common Stock Value | $44.5M | $39.7M | $913.8K | $162.5K | $62.1K | $34.7K | $22.7K | $20.0K | ||
| Assets Noncurrent | $367.0K | $8.9M | $10.0M | $11.1M | $11.3M | $2.1M | $1.9M | $1.6M | ||
| Assets Current | $21.3M | $14.2M | $19.5M | $22.5M | $23.2M | $19.6M | $15.6M | $6.1M | ||
| Assets | $21.7M | $23.1M | $29.6M | $33.5M | $34.5M | $21.7M | $17.5M | $7.7M | ||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -$1.1M | -$1.0M | -$197.6K | $956.1K | $527.8K | -$590.7K | $50.4K | $257.4K | ||
| Accounts Receivable Net Current | $1.3M | $1.3M | $1.3M | $3.3M | $4.5M | $3.8M | $4.2M | $2.6M | ||
| Accounts Payable Current | $1.2M | $1.3M | $1.4M | $1.5M | $1.5M | $1.9M | $1.7M | $2.4M | ||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect | $6.1M | -$5.3M | $1.8M | $2.2M | $6.1M | -$2.0M | ||||
| Liabilities Noncurrent | $211.7K | $294.7K | $365.8K | $6.3K | $36.5K | $41.7K | ||||
| Finite Lived Intangible Assets Net | $27.9K | $38.8K | $45.8K | $50.1K | $61.1K | $60.7K | ||||
| Refund Liabilities | $1.4K | $360.9K | -$337.6K | -$40.0K | -$78.3K | |||||
| Bad Debt Provision | -$2.9M | -$477.3K | -$1.2M | -$41.2K | -$66.9K | |||||
| Refunds Liabilities | $112.0K | $122.8K | $472.3K | $113.6K | $78.3K |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Net Cash Provided By Used In Operating Activities | -$2.3M | -$1.9M | -$80.8K | $268.3K | -$1.3M | $934.2K | $239.2K | $1.9M | $293.0K |
| Net Cash Provided By Used In Investing Activities | $63.5K | $26.4K | -$12.3K | -$46.9K | -$5.8M | -$5.5M | -$610.1K | -$1.1M | -$186.3K |
| Net Cash Provided By Used In Financing Activities | $8.4M | -$2.6M | $2.9M | $1.6M | $12.4M | $3.0M | $9.0M | -$314.2K | -$50.6K |
| Increase Decrease In Prepaid Supplies | $287.8K | -$29.4K | -$138.00 | -$480.9K | $341.1K | -$154.7K | $106.5K | $82.6K | -$219.8K |
| Increase Decrease In Prepaid Deferred Expense And Other Assets | $223.5K | -$143.2K | -$50.3K | -$1.0M | $1.0M | $361.6K | -$144.8K | $809.7K | -$296.2K |
| Increase Decrease In Inventories | $14.5K | $219.6K | -$409.0K | $180.8K | -$38.6K | -$39.7K | -$154.5K | $274.4K | -$384.2K |
| Increase Decrease In Accrued Income Taxes Payable | -$15.8K | $1.6K | $27.1K | -$32.0K | $91.4K | -$22.3K | $249.6K | $519.6K | $388.0K |
| Increase Decrease In Accounts Receivable | $257.1K | $321.4K | -$912.9K | -$831.5K | $519.2K | -$104.0K | $1.8M | -$384.4K | $943.0K |
| Increase Decrease In Accrued Liabilities | $298.8K | -$53.8K | -$46.4K | $384.8K | $488.9K | $1.6M | $310.3K | -$203.9K | -$248.7K |
| Proceeds From Repayments Of Related Party Debt | -$1.7M | -$2.2M | -$231.7K | $12.5M | -$3.2M | $2.5M | |||
| Increase Decrease In Customer Advances | $94.3K | -$186.4K | -$62.5K | $247.6K | -$216.5K | -$331.7K | $78.7K | ||
| Increase Decrease In Notes Receivables | -$32.9K | $35.1K | -$18.5K | -$60.3K | -$202.6K | $287.5K | |||
| Depreciation Depletion And Amortization | $82.3K | $203.2K | $250.2K | $320.0K | $345.4K | $331.8K | $180.9K | $129.4K | |
| Payments For Construction In Process | $1.6K | $14.7K | $275.8K | $63.0K | $593.7K | ||||
| Increase Decrease In Accounts Payable | -$114.1K | -$29.3K | $9.7K | -$22.8K | $302.3K | -$567.3K | $966.6K | -$1.5M | |
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | -$65.1K | -$765.2K | -$1.0M | $394.1K | $784.5K | -$466.8K | |||
| Payments To Acquire Intangible Assets | $2.0K | $7.1K | $70.7K | $60.9K | $78.3K | $11.3K | $21.0K | $7.1K | |
| Payments To Acquire Other Property Plant And Equipment | $60.9K | $78.3K | $130.8K | $535.8K | |||||
| Proceeds From Convertible Debt | $1.6M | $1.1M | $3.7M | $2.8M | $10.0M | ||||
| Share Based Compensation | $352.1K | $554.6K | $2.3M |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Diluted EPS * | -$2.32 | -$28.58 | -$177.84 | -$137.92 | -$3.82 | $1.66 | $0.08 | $0.06 | $0.06 |
| Common Stock Shares Issued | 13.8M | 13.8M | 457.4K | 128.8K | 776.3K | 9.7M | 22.7M | 20.0M | 9.7M |
| Common Stock Par Or Stated Value Per Share | $2.00 | $2.00 | $0.08 | $0.08 | $0.00 | $0.00 | $0.00 | ||
| Common Stock Shares Outstanding | 13.8M | 13.8M | 457.4K | 2.0M | 776.3K | 8.7M | 22.7M | 20.0M | |
| Weighted Average Number Of Shares Outstanding Basic | 1.4M | 108.4K | 33.4K | 41.6K | 719.5K | 309.1K | 20.6M | 20.0M | 20.0M |
| Earnings Per Share Basic | $-2.32 | $-28.58 | $-177.84 | $-137.92 | $-3.82 | $33.28 | $0.08 | $0.06 | $0.06 |
| Weighted Average Number Of Diluted Shares Outstanding | 1.4M | 108.4K | 33.4K | 41.6K | 719.5K | 20.6M | 20.0M | 20.0M |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|
| Supplies | $301.1K | $14.9K | $46.3K | $50.3K | $519.8K | $154.1K | $319.1K | $227.2K | |
| Interest Paid Net | $21.2K | $24.5K | $13.0K | $3.2K | $3.1K | $10.4K | $51.8K | $22.4K | $197.00 |
| Customer Advances Current | $165.5K | $77.4K | $257.4K | $298.0K | $57.6K | $292.9K | |||
| Additional Paid In Capital | $35.6M | $31.0M | $25.3M | $17.2M | $8.0M | $1.5M | |||
| Issuance Of Shares For Convertible Notes Principal And Interest Partial Settlement | 2.1M | 2.8M | 2.9M | 7.7M | 6.8M | ||||
| Short Term Borrowings | $702.2K | $493.1K | $167.5K | ||||||
| Selling Expense | $924.5K | $1.6M | $1.6M | $1.6M | $512.5K | $144.4K | |||
| Convertible Note Accretion Of Financing Cost | -$520.8K | -$292.8K | -$335.7K | -$29.9K | $1.1M | $3.4M | |||
| Stock Issued During Period Value Conversion Of Units | $2.1M | $2.8M | $2.9M | $7.7M | $6.4M |
Most recent annual filing with the SEC: July 31, 2025
Data sourced from SEC EDGAR public filings as of August 5, 2026.